Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Unrealized Gains on Investments

Unrealized Gains on Investments at other companies

Gilead Sciences logo
Gilead SciencesGILD
$11M
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Allogene Therapeutics logo
Allogene TherapeuticsALLO

Other financials

Income statement

See full
Revenue-
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$548.55M+780%
Enterprise value$256.48M+450%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Reported directly by Artiva Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029
Line itemCLASSIFICATIONMATURITYAMORTIZEDCOSTGROSSUNREALIZEDGAINSGROSSUNREALIZEDLOSSESFAIRMARKETVALUE
Cash and money market fundsCash and cash equivalentsLess than three months$301,454$301,454
Commercial paperShort-term investments1 year or less12,357(11)12,346
Government and government agency bondsShort-term investments1 year or less16,3315(1)16,335
Corporate debt obligationsShort-term investments1 year or less18,264(8)18,256
Corporate debt obligationsShort-term investmentsGreater than 1 year1,009(6)1,003
Total cash, cash equivalents and short-term investments$349,415$5$(26)$349,394

Item 1. Financial Statements

FAQ

What is Artiva Biotherapeutics, Inc.'s unrealized gains on investments?
Artiva Biotherapeutics, Inc. (ARTV) reported unrealized gains on investments of $5K in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s unrealized gains on investments changed year-over-year?
Artiva Biotherapeutics, Inc.'s unrealized gains on investments decreased by 90.6% year-over-year, from $53K to $5K.
What is the long-term trend for Artiva Biotherapeutics, Inc.'s unrealized gains on investments?
Over 2 years (2023 to 2025), Artiva Biotherapeutics, Inc.'s unrealized gains on investments has grown at a -40.8% compound annual growth rate (CAGR), from $308K to $108K.
What does unrealized gains on investments mean?
The total unrealized gains on investments, typically related to available-for-sale securities.

Ask your AI about Artiva Biotherapeutics, Inc.'s unrealized gains on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude